Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

PALO ALTO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a Master Distributor Agreement with Devart Middle East Food Supplements (“Devart Middle East”), as Master Distributor, and CH Trading Group LLC (“CH Trading Group”), as Territories Distributor, to expand the distribution of ZTlido into the countries of Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa (“Designated Territories”).

The Master Distributor Agreement is an outgrowth Scilex’s existing Product Distribution Agreement with CH Trading Group, under which CH Trading Group is continuing the process of expanding commercialization of ZTlido in the Middle East and North/South Africa markets and has the opportunity to distribute across the broader Islamic world and further expand the relationship for other products in Scilex’s non-opioid pain portfolio.

Under the Master Distributor Agreement, Devart Middle East assumes the responsibility, among other things, of promoting, marketing, selling and distributing ZTlido, and potentially other Scilex products, through a network of business associates, into the above Designated Territories.

ZTlido is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN). ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.

• Over one million patients are estimated to have been treated with ZTlido in the United States since its launch according to Symphony Health prescription data.
• ZTlido is now the number one prescribed, non-opioid, branded, pain medication by pain specialists in the United States, based on Symphony Health prescription data gathered for 2023.
• In the U.S., patients report 89% satisfaction with ZTlido, in a 2023 patient survey conducted by Scilex (n=100, rating as “completely” or “mostly” satisfied with ZTlido treatment).